effect of antihypertensive combination therapy with either CCB or diuretics on irbesartan on hypertensive patient with metabolic syndrome:A randomised controlled trial

effect of antihypertensive combination therapy with either CCB or diuretics on irbesartan on hypertensive patient with metabolic syndrome:A randomised controlled trial - effect of antihypertensive combination therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003458

Enrollment

Registered

2010-04-07

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertensive patient with metabolic syndorome

Interventions

irbesartan(50-200mg)+amlodipine(2.5-10mg)/day irbesartan(50-200mg)+indapamide(0.5-2mg)/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: hypertennsive patients with metabolic syndrome 1)Hypertention ARB other than irbesartan have been administered for one month or more. The home blood pressure value is SBP125mmHg or DBP75mmHg and above the value of the blood pressure of the examination room is SBP130mmHg or DBP80mmHg or more. 2)Patient who fill metabolic syndrome criteria standard

Exclusion criteria

Exclusion criteria: 1)Hypersensitivity 2)Pregnant woman or possibility of pregnancy 3)Diuretic and CCB are administered 4)Steroid or the immunosuppressive agent is taken 5)Patient who judged that doctor in charge is improper

Design outcomes

Primary

Measure	Time frame
degree and accomplishment of a BP recommended goal	—

Secondary

Measure	Time frame
clinical parameters fasting glucose levels HOMA-R TG HDL-C LDL-C u-albumin:creatinine ratio e-GFR ICAM-1	—

Countries

Japan

Contacts

Public ContactDaisuke Koya

Kanazawa Medical University Diabetes & Endocrinology

koya0516@kanazawa-med.ac.jp076-286-2211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026